US FDA Needs More Time To Review Clinuvel’s Scenesse For Phototoxicity

The user fee goal date for the Food and Drug Administration’s review of Scenesse has been put back from July to October to allow more time to examine the therapy’s benefit-risk profile.

Delayed
The FDA has extended the review deadline for Scenesse

The US Food and Drug Administration has extended its review of Clinuvel’s phototoxicity therapy, Scenesse (afamelanotide), by three months to allow the agency to complete its assessment of the drug’s benefit-risk profile.

The agency’s Division of Dermatology and Dental Products (DDDP) has changed the original Prescription Drug User Fee Act user fee...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America